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Aims Monocytes play an important role in hypertension. Circulating monocytes in humans exist as classical, intermediate,
and non-classical forms. Monocyte differentiation can be influenced by the endothelium, which in turn is activated
in hypertension by mechanical stretch. We sought to examine the role of increased endothelial stretch and hyper-
tension on monocyte phenotype and function.
....................................................................................................................................................................................................
Methods
and results
Human monocytes were cultured with confluent human aortic endothelial cells undergoing either 5% or 10% cyclical
stretch. We also characterized circulating monocytes in normotensive and hypertensive humans. In addition, we quan-
tified accumulation of activated monocytes and monocyte-derived cells in aortas and kidneys of mice with Angiotensin
II-induced hypertension. Increased endothelial stretch enhanced monocyte conversion to CD14þþCD16þ intermedi-
ate monocytes and monocytes bearing the CD209 marker and markedly stimulated monocyte mRNA expression of
interleukin (IL)-6, IL-1b, IL-23, chemokine (C-C motif) ligand 4, and tumour necrosis factor a. STAT3 in monocytes
was activated by increased endothelial stretch. Inhibition of STAT3, neutralization of IL-6 and scavenging of hydrogen
peroxide prevented formation of intermediate monocytes in response to increased endothelial stretch. We also found
evidence that nitric oxide (NO) inhibits formation of intermediate monocytes and STAT3 activation. In vivo studies
demonstrated that humans with hypertension have increased intermediate and non-classical monocytes and that inter-
mediate monocytes demonstrate evidence of STAT3 activation. Mice with experimental hypertension exhibit in-
creased aortic and renal infiltration of monocytes, dendritic cells, and macrophages with activated STAT3.
....................................................................................................................................................................................................
Conclusions These findings provide insight into how monocytes are activated by the vascular endothelium during hypertension.
This is likely in part due to a loss of NO signalling and increased release of IL-6 and hydrogen peroxide by the dys-
functional endothelium and a parallel increase in STAT activation in adjacent monocytes. Interventions to enhance
bioavailable NO, reduce IL-6 or hydrogen peroxide production or to inhibit STAT3 may have anti-inflammatory
roles in hypertension and related conditions.
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1. Introduction
In 2016, hypertension was ranked as the leading risk factor for global
burden of disease in both developed and underdeveloped countries.1 In
the past 10 years, it has become evident that activated immune cells infil-
trate the kidney and other organs and that these cells contribute to the
end-organ damage in this disease.2 In particular, monocytes seem to play
a particularly important role in hypertension. Wenzel et al. showed
selective ablation of lysozyme M-positive (LyzMþ) myelomonocytic
cells in mice completely prevented Angiotensin II (Ang II) induced
hypertension and prevented the endothelial dysfunction and vascular
oxidative stress generally observed in this model.3
The mechanism by which monocytes promote hypertension remains
undefined but likely involves transformation into activated states or into
other cell types, including macrophages and monocyte-derived dendritic
cells (DCs). Indeed, De Ciuceis et al. found that mice lacking macrophage
colony-stimulating factor, required for the stimulation of macrophage
formation from monocytes, are protected against blood pressure (BP)
elevation.4 Furthermore, these mice are protected from vascular remod-
elling, vascular superoxide production and the alteration of
endothelium-dependent vasodilation that normally accompanies hyper-
tension.4 Likewise, monocyte-derived DCs seem to play a critical role in
hypertension. DCs potently activate T cells, which are essential for full
development of hypertension.5 We have shown that in hypertension
DCs accumulate isolevuglandin (IsoLG)-adducted proteins that are im-
munogenic, and that adoptive transfer of DCs from hypertensive mice
primes hypertension in recipient mice. DCs of hypertensive mice pro-
duce large quantities of cytokines including IL-6, IL-23, and TNFa and ex-
hibit enhanced ability to drive proliferation of T cells from other
hypertensive mice.6 These cytokines are activated in response to the
phosphorylation of signal transducer and activator of transcription 3
(STAT3),7 and their production can skew T cells towards T helper 17
(TH17) differentiation. The production of IL-17 by T cells is critical for
maintenance of Ang II-induced hypertension and vascular dysfunction.8
Indeed, we have observed increased IL-17A producing T cells in the cir-
culation of hypertensive humans.9
Circulating monocytes in humans have been classified into three sub-
populations depending on their surface expression of the toll-like recep-
tor 4 (TLR4) co-receptor CD14 and the FccIII receptor CD16.10 Most
circulating monocytes are classified as ‘classical’ and exhibit surface ex-
pression if CD14 and little or no CD16 (CD14þþCD16-). These are
thought to represent cells newly released from the bone marrow, and
they circulate for approximately 1 day before either dying, transmigrating
or transforming into another phenotype.11 Non-classical monocytes,
characterized by their expression of CD16 and low levels of CD14 or
CD14lowCD16þþ, and are known to expand in inflammatory states.
Upon stimulation, these CD14lowCD16þþ cells exhibit increased pro-
duction of TNFa.12 In 1988, a small population of monocytes expressing
both CD14 and CD16 was identified,13 subsequently termed intermedi-
ate monocytes or CD14þþCD16þ.14 These cells are also expanded in
inflammatory states such as rheumatoid arthritis, psoriasis, and periph-
eral artery disease.15–18 Recent deuterium labelling studies indicate that
intermediate and non-classical monocytes arise sequentially from the
CD14 population.11 When placed in culture, classical monocytes acquire
increasing levels of CD16 with time.13 The population of monocytes that
gives rise to human monocyte-derived DCs remains poorly defined, but
includes CD16þ cells.19 Another population are monocytes that express
the DC-specific intracellular adhesion molecule (ICAM)-3 grabbing non-
integrin (DC-SIGN) or CD209 DC receptor, which interacts with the
leukocyte cell-derived chemotaxin 2 (LECT2). LECT2 is crucial for the
process of adhesion and rolling of DCs on endothelial cells and can me-
diate macrophage activation and protection against bacterial sepsis.20
The expression of CD209 on DCs is considered a marker of
maturation.21
A potential source of monocyte activation in hypertension is interac-
tion of these cells with the vascular endothelium. In this regard,
Randolph et al. showed that monocytes cultured with endothelial cells
that had been stimulated with IL-1b, LPS, or zymosan particles differenti-
ate into either DCs or macrophages depending on reverse transmigra-
tion through the endothelium.22 These investigators further showed that
CD16þ cells are more likely to reverse transmigrate and that reverse
transmigration of monocytes promotes the formation of a CD16þ pop-
ulation.23 A feature of hypertension that can activate the endothelium is
increased mechanical stretch. Indeed, increased cyclic stretch activates
transcription factors including AP1, the cAMP responsive binding pro-
tein, NFjB in human endothelial cells,24 and a variety of signalling mole-
cules including ERK1/2, the focal adhesion kinase pp125fak, PI3 kinase,
and p21Ras.25–27 Gene array studies have indicated that endothelial
stretch increases expression of inflammatory mediators including IL-6,
IL-8, the monocyte chemoattractant protein 1 (MCP-1) and the vascular
cell adhesion molecule-1 (VCAM-1).28 These events promote monocyte
adhesion, rolling, and transmigration through the endothelium,29 and
some are redox sensitive.30 Hishikawa and Luscher showed that 10%
stretch of human aortic endothelial cells (HAECs) enhances superoxide
production, mediated initially by the NADPH oxidase and subsequently
by the nitric oxide (NO) synthase depending on the presence of
tetrahydrobiopterin.31
In the present study, we examined the role of endothelial mechanical
stretch and STAT3 in promoting transformation of co-cultured human
monocytes into the intermediate-phenotype and to cells bearing DC
properties. We also examined monocyte subsets and STAT phosphory-
lation status in humans with hypertension. Our findings provide new in-
sight into how altered mechanical forces in the vessel can promote
immune activation.
2. Methods
2.1 Human subjects
We performed three studies: one involved obtaining monocytes from
normotensive subjects to analyse their response to endothelial stretch.
For this analysis, we included male and female normotensive participants
who had BP between <135/80 mmHg. In a second study, we examined
the phenotype of circulating monocytes from 20 normotensive subjects,
52 subjects with mild hypertension (systolic BP from 130 to 140 mmHg),
and 60 subjects with more severe hypertension (systolic
BP >140 mmHg). In a third study, we recruited 15 normotensive subjects
and 12 hypertensive subjects for analysis of phospho-STAT levels in
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circulating monocytes. For this third study, participants were considered
hypertensive if they had a systolic BP higher than 140 mmHg, a diastolic
BP higher than 90 mmHg or had a diagnosis of hypertension and were
currently treated with anti-hypertensive agents. Normal and hyperten-
sive volunteers were included between ages 18 and 55 years.
Exclusion criteria included the following: (i) autoimmune disease or
history of inflammatory diseases; (ii) recent vaccinations within the last
3 months; (iii) confirmed or suspected causes of secondary hypertension;
(iv) severe psychiatric disorder; (v) HIV/AIDS; (vi) current treatment
with steroids or antihistamines; (vii) liver or renal disease and (viii)
history of cancer. Protocol 1 and 3 were approved by the Vanderbilt
Institutional Review Board and conformed to standards of the US
Federal Policy for the Protection of Human Subjects. The Ethics
Committee of Jagiellonian University approved protocol two. Written
informed consent was obtained from all patients.
2.2 Monocyte isolation and monocyte-
HAECs cultures
HAECs (Lonza, Walkersville, MD, USA) were grown to confluency on
flexible six-well culture plates that permit uniaxial stretch (FlexcellVR
International Corporation, Burlington, NC, USA). These were coated
with Collagen I and 1% gelatin crosslinked with 0.05% of glutaraldehyde.
Cells were fed every other day with EBM-2 medium (Lonza) containing
EGM-2 growth factors and supplements and 2% foetal bovine serum and
stored in 37C incubator with 5% CO2.
Peripheral blood mononuclear cells (PBMCs) from each volunteer
were isolated initially by Ficoll-density gradient centrifugation and subse-
quently CD14þ monocytes were further isolated from PBMCs using
negative selection with the monocyte isolation kit (Miltenyi Biotec 130-
096-537; Miltenyi Biotec, Auburn, CA, USA) as previously described.32
Monocytes from each volunteer were added to the endothelial cells pre-
viously grown on UniflexVR six-well culture plates so that we could simul-
taneously examine the response of monocytes to endothelial cells
undergoing 5% and 10% uniaxial stretch. In indicated experiments, 6%
and 8% stretch was applied. In some experiments, one million human
monocytes were added to UniflexVR six-well culture plates coated with
Collagen I and PronectinVR (RGD) (FlexcellVR International Corporation)
in the absence of HAECs. Uniaxial cyclical mechanical stretch was ap-
plied to the endothelial cell monolayers at 5% and 10% elongation strain,
1 Hz, and 1=2 sine curve.
2.3 T-cell proliferation assay
One million CD14þ monocytes were exposed to endothelial cells un-
dergoing either 5% or 10% stretch as described above. Forty-eight hours
later, the endothelial cells were removed by Fluorescence Activated
Cell-Sorting (FACS) using CD31 staining. The same subjects returned
on this day, additional blood was sampled and T cells were harvested
from PBMCs using negative selection (130-096-535; Miltenyi Biotec).
These T cells were loaded with carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen) and cultured with the sorted monocytes at a 1:10 ra-
tio for 7 days. Proliferation was measured by the CFSE dilution using
flow cytometry.
2.4 Animals
Wildtype (WT) C57Bl/6 male mice, obtained from The Jackson
Laboratory were studied at 3 months of age. Ang II (490 ng/kg/min) or
vehicle (sham) was infused for 6 days via osmotic minipumps (Alzet,
Model 2002; DURECT Corporation, Cupertino, CA, USA) as previously
described.5,6 All animal procedures were approved by Vanderbilt
University’s Institutional Animal Care and Use Committee (IACUC)
where the mice were housed and cared for in accordance with the
Guide for the Care and Use of Laboratory Animals, US Department of
Health and Human Services.
2.5 Flow cytometry
Monocyte populations were collected from the endothelial/monocyte
co-cultures by digesting the Collagen I and 1% gelatin coating with
Collagenase A and B (1 mg/mL) and DNAse I (100lg/mL) in RPMI 1640
medium with 10% FBS for 30 min at 37C. This procedure harvested not
only cells in suspension, but also cells adhering to the endothelium and
those that potentially transmigrated to the subendothelial collagen/gela-
tin layer. In mice, organs were transcardially perfused by physiological
pressure with saline solution prior to organ collection. Single cell suspen-
sions were prepared from aortas and kidneys as previously described.33
Flow cytometry was performed as previously described.32 Gates for
each antibody stain were determined by flow minus one (FMO) controls
and confirmed using isotype controls. We employed live/dead stains
to eliminate non-viable cells and selected only single cells for analysis
(Figure 1A). For the detection of murine monocytes, DCs and macro-
phages in the aorta and kidney we employed a gating strategy that effec-
tively discriminates between these subsets as previously described.34 For
freshly isolated human monocytes we used a gating strategy as described
by Urbanski et al.35
2.6 Co-immunoprecipitation, quantitative
RT-PCR and ELISA
For co-immunoprecipitation (co-IP) studies, monocytes were isolated
from the monocyte-HAEC cultures using a negative selection for human
CD31 (Miltenyi Biotec). co-IP was performed as previously described.32
The bands of interest were normalized to total STAT3. For RT-PCR
monocytes were again isolated from the endothelium and lysed in RLT
buffer and RNA was extracted using the RNeasy Mini Kit (Qiagen,
Germantown, MD, USA) and RT-PCR was performed according to the
manufacturer’s instructions using both iScript cDNA synthesis kit
(BioRad, Hercules, CA, USA) or the High Capacity cDNA reverse tran-
scriptase kit (Applied Biosystems, Foster City, CA, USA). Samples were
evaluated for human IL-6, IL-1b, IL-23, TGF-b, CD168, p22phox, CCL4,
IL-18, CCL2, MMP8, and TNFa using Taqman primers. Relative quantifi-
cation was determined using the comparative CT method where sam-
ples were normalized to GAPDH and calibrated to the average of the
control group (5% stretch). LECT2, IL-6, and High Mobility Group Box-1
(HMGB-1) protein were quantified using ELISA kits from LS-Bio,
Affymetrix and IBL International, respectively.
2.7 Visualization of monocytes with
endothelial cells in co-cultures
One to two million human monocytes isolated from PBMCs of normo-
tensive people were incubated with 12mM of CellTrackerTM Green
CMFDA Dye (C2925, ThermoFisher Scientific, Waltham, MA, USA) in
EBM2 medium (Lonza) for 30 min at 37C according to the manufac-
turer’s instructions. After incubation, cells were washed with medium
and one million fluorescently tagged monocytes were added to wells
containing either confluent HAECs on Collagen I/gelatin coated six-well
stretch plates or without the presence of endothelial cells in six-well
stretch plates coated with Collagen I or PronectinVR (RGD, FlexcellVR
International Corporation). For imaging, endothelial-containing cultures
Endothelial activation of monocytes in hypertension 1549
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Figure 1 Hypertensive mechanical stretch in human endothelial cells promotes monocyte activation and differentiation. Human CD14þ monocytes
were isolated by magnetic sorting from PBMCs of normal human volunteers and cultured with HAECs exposed to cyclical stretch. (A) Schematic of the
experimental design and (B) gating strategy for phenotyping human monocytes including classical (CD14þþCD16-), intermediate (CD14þþCD16þ) and
non-classical monocytes (CD14lowCD16þþ). (C) Changes in numbers of cells for each subject are depicted by connected lines for CD14þþCD16þ (n = 9)
and (D) CD14þþCD209þ, (E) CD14lowCD16þþ, (F) macrophage population (CD14þCD163þ), (G) CD14þþCD16-, (H) CD14-CD83þ (n = 10).
(I) Relative monocyte mRNA expression of IL-6, IL-1b, IL-23, TNFa, and CCL4 in adhered monocytes and in monocytes in suspension (5%, n = 15; 10%,
n = 16). (J) Monocyte-HAECs cultures were stretched to either 5% or 10% for 48 h followed by sorting monocytes from HAECs using CD31þ isolation kit
and FACS. Monocyte populations were cultured with CFSE-labelled T cells isolated from PBMCs of the same participants. Seven days later, we measured
proliferation in the CD4þ and CD8þ T-cell populations by flow cytometry. Changes in number of proliferated CD4þ and CD8þ T cells after 7 days in cul-
ture for each subject are depicted by connected lines (n = 7). Comparisons were made using one-tail paired t-tests (*P < 0.05, **P < 0.01).
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or monocyte alone cultures were exposed to either 5% or 10% levels of
continuous uniaxial stretch for 24 h. Cells were subsequently washed
with 1 PBS and the remaining cells were fixed with 4% paraformalde-
hyde (PFA) solution for 15 min at room temperature. The cells were
then permeabilized with 0.5% Triton X-100 (Sigma) in 1 PBS for 30 min
at room temperature. Cells underwent several washes in PBS and were
blocked with goat serum solution (5% goat serum and 2.3% glycine in
PBS) for 1 h at room temperature. Cultures with endothelial cells were
then stained with the primary purified anti-human CD54 or ICAM-1
(HA58, Biolegend, San Diego, CA, USA) at a 1:100 concentration in goat
serum solution for 1 h at room temperature. Cells were then stained
with the ReadyProbes secondary antibodies conjugated with Alexa
FluorTM 594 dyes goat anti-mouse antibody (R37121, ThermoFisher
Scientific) using one drop per millilitre of PBS and incubation for 30 min
at room temperature. Finally, all plates’ flexible membranes were
mounted unto glass slides and ProLongVR Gold antifade reagent with
DAPI (ThermoFisher Scientific) was used to stain for the nucleus before
adding the coverslip. Imaging of the slides was performed using an
EVOSTM FL Imaging System (ThermoFisher Scientific). Adhered mono-
cytes were counted using ImageJ software in three random fields and an
average was calculated and used as a graphing representative.
For imaging with confocal microscopy membranes were fixed in 4%
PFA for 15 min at room temperature, washed with PBS and then blocked
for one hour in Dako Serum Free Protein Block (DSFPB) (Agilent
Technologies, Santa Clara, CA). Membranes were incubated with puri-
fied anti-CD83 antibody (BioLegend; category number 305301) or iso-
type matched control (Biolegend; category number 400102) in DSFPB
overnight at 4C, washed in PBS, and then probed with Alexa Fluor 647
labelled anti-Murine IgG raised in goat (ThermoFisher Scientific) for
30 min. Following washing in PBS, membranes were stained with anti-
CD31-FITC (BioLegend; category number 303103) and anti-CD14-
Alexa Fluor 594 (BioLegend; category number 325630) for 2 h at room
temperature. Samples were washed in PBS and counterstained with
DAPI for 10 min. Membranes were washed in PBS and then mounted on
glass-bottomed dishes. Immunofluorescent images were then acquired
using a Zeiss Cell Observer SD confocal fluorescent microscope (Zeiss,
Oberkochen, Germany).
2.8 Visualization of monocytes/
macrophages in aortic sections of WT
C57Bl/6 mice
C57Bl/6 mice were infused with either sham or Ang II for 2 weeks and
aortas were harvested and embedded in paraffin for sectioning. Paraffin
sections were dehydrated with ethanol and fixed with 10% formalin for
20 min at room temperature. The cells were then permeabilized with
0.5% Triton X-100 (Sigma) in 1X PBS for 30 min at room temperature.
Cells underwent several washes in PBS and were blocked with foetal se-
rum solution (5% goat serum and 2.3% glycine in PBS) for 1 h at room
temperature. Sections were stained with the primary purified anti-
mouse F4/80 and pSTAT3 (Y705) at a 1:100 and 1:50, respectively, in se-
rum at 4C overnight. Cells were then stained with secondary antibodies
conjugated Alexa FluorTM donkey anti-rat and anti-rabbit antibodies
(Invitrogen) using one drop per millilitre of PBS and incubation for 1 h
and 30 min at room temperature. Finally, we added ProLongVR Gold anti-
fade reagent with DAPI (ThermoFisher Scientific) to stain for the nucleus
before adding the coverslip. Imaging of the slides was performed using an
EVOSTM FL Imaging System (ThermoFisher Scientific).
2.9 Reagents
All reagents were obtained in the highest purity available. These included
Stattic, Tempol, Tofacitinib citrate, PEG-Catalase, Angiotensin II and
Ebselen from Sigma, DETA-NONOate from Cayman Chemical
Company, and the anti-IL-6 neutralizing antibody was from BioLegend
(clone MQ2-13A5). L-Nitroarginine methyl ester (L-NAME) was from
Abcam.
2.10 Statistics
All data are expressed as mean ± SEM. One tailed-paired and unpaired
Student’s t-tests were used to compare two groups. In case of the non-
normality, the non-parametric test one-tailed Mann–Whitney U test was
used. When examining the effect of varying endothelial percent stretch
on monocyte transformation to the intermediate phenotype, we
employed one-way ANOVA with Student Newman Keuls post hoc test.
When examining the effect of DETA-NONOate, we employed the
Friedman’s multiple comparison test followed by the Dunn’s post hoc
test. To compare the distribution of monocyte subtypes in normoten-
sive humans vs. humans with mild or severe hypertension, we employed
one-way ANOVA. To compare pSTAT levels in monocytes from nor-
motensive and hypertensive subjects, we employed two-way ANOVA
with Student Newman Keuls post hoc test. Categorical data were
analysed using v2 analysis. P values are reported in the figures and were
considered significant when <0.05. Power analyses for the various
experiments are provided in Supplementary material online, Table S1.
3. Results
3.1 Hypertensive mechanical stretch in
human endothelial cells promotes
monocyte activation and differentiation
It has been previously reported that endothelial cells activated by zymo-
san, LPS or IL-1b can promote conversion of monocytes to DCs.22
A feature of hypertension that activates endothelial cells is increased me-
chanical stretch. We therefore isolated CD14þmonocytes from PBMCs
of normotensive humans and co-cultured these with HAECs undergoing
5% or 10% mechanical stretch for 48 h as shown by the illustration in
Figure 1A. The intermediate monocyte CD14þþCD16þ population
(Figure 1B and C) and the CD14þþCD209þ population (Figure 1B and D)
were significantly increased in the co-cultures with HAECs undergoing
10% compared with 5% stretch. The non-classical monocyte population
defined as CD14lowCD16þþ displayed a trend to increase in response
to 10% endothelial stretch (Figure 1E). The macrophage population de-
fined as CD14þCD163þ (Figure 1F) and the classical monocyte popula-
tion defined as CD14þþCD16- (Figure 1G) were not different between
experimental groups. Another marker of monocyte activation and DC
development is CD8336; however, only a few monocytes expressed
CD83þ after co-culture (Figure 1H) and these were not changed by en-
dothelial stretch. Intermediate levels of endothelial stretch ranging from
6% to 8% failed to alter the phenotype of human monocytes (see
Supplementary material online, Figure S1A). There was also no difference
in the percent of live cells between the 5% and 10% stretch (see
Supplementary material online, Figure S1B). In keeping with the state of
monocyte activation, 10% endothelial stretch promoted a striking upre-
gulation of monocyte mRNA for the cytokines IL-6, IL-1b, IL-23, TNFa,
and CCL4 compared with 5% stretch (Figure 1I). In contrast, stretch did
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CD168 (see Supplementary material online, Figure S2).
It has been reported that monocytes can enter tissues and re-emerge
into the circulation without differentiation into macrophages or DCs.34
These cells can transport antigen to lymph nodes and have enhanced
ability to drive T-cell proliferation. To determine if endothelial stretch
conveys this property to monocytes, we obtained T cells from the same
monocyte donors after their monocytes had been exposed to endothe-
lial cell stretch for 48 h. These autologous T cells were labelled with
CFSE and co-cultured with monocytes for 7 days and their proliferation
was examined by CFSE dilution. As shown in Figure 1J, monocytes previ-
ously exposed to 10% stretched endothelial cells for 48 h exhibited an
enhanced ability to drive CD4þ and CD8þ T-cell proliferation when
compared with the cells from the 5% stretched endothelial cell cultures.
3.2 Hypertensive mechanical stretch on
endothelial cells promotes STAT3
activation in co-cultured monocytes
Increased expression of IL-6, IL-1b, and IL-23 resemble a cytokine re-
sponse typical of STAT3 signalling.37 In addition, STAT3 activation has
been identified as a checkpoint for FLT-3-regulated DC development.38
We therefore sought to determine whether STAT3 plays a role in
monocyte activation and differentiation when exposed to HAECs under-
going stretch. STAT3 activation occurs upon phosphorylation of tyro-
sine (Y) 705 and/or serine (S) 727. When activated, STAT3 can also
form a heterodimer with STAT1. Using intracellular staining we found
that the CD14þþCD16þ intermediate (Figure 2A, C–E) and the
CD14þþCD209þ populations (Figure 2B, F–H) had a significant increase
Figure 2 Effect of endothelial stretch on STAT3 activation in co-cultured monocytes. Human CD14þ monocytes were isolated from buffy coats of nor-
mal human volunteers and cultured with HAECs exposed to 5% or 10% cyclical stretch. (A) Representative flow cytometry plots are shown for intracellular
staining of STAT3 phosphorylation in the tyrosine (Y) 705 and the serine (S) 727 and STAT1 phosphorylation in the Y701 in the CD14þþCD16þ intermedi-
ate monocytes and (B) the CD14þþCD209þ cells in the 5% stretch (blue), 10% stretch (red), and the dashed line represents FMO control. (C–E) Changes
in numbers of intermediate monocytes between 5% and 10% endothelial cell stretch expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 are depicted by
connected lines. (F–H) Changes in numbers of CD14þþCD209þ cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 between 5% and 10% endothelial
cell stretch. Comparisons were made using one-tail paired t-tests (n = 9, *P < 0.05, **P < 0.01).
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in pSTAT3 (Y705), pSTAT3 (S272), and pSTAT1 when cultured with en-
dothelial cells undergoing 10% stretch. We also observed an increase in
STAT3 and STAT1 phosphorylation in cells that remained
CD14þþCD16-, but not in the non-classical monocytes (see
Supplementary material online, Figure S3A and B). Given that both
STAT3 and STAT1 are activated in monocytes that underwent transfor-
mation, we considered the possibility that this involved heterodimeriza-
tion of the two STAT isoforms, however, we were unable to detect
association of the two using co-immunoprecipitation (see
Supplementary material online, Figure S3C). Moreover, we were unable
to detect fluorescence resonance energy transfer between STAT1 and
STAT3 using flow cytometry-based method (data not shown).
3.3 STAT3 plays a role in monocyte
differentiation and activation during
hypertensive mechanical stretch of
endothelial cells
To determine a specific role of STAT3 in differentiation of monocytes
during stretch, we employed Stattic, a non-peptidic small molecule that
selectively inhibits the function of the STAT3 SH2 domain.39 Addition of
Stattic to the cell culture reduced formation of the CD14þþCD16þ in-
termediate monocyte population (Figure 3A and C) and CD14þþCD209þ
DC population in response to 10% stretch (Figure 3B and D). Likewise,
Stattic reduced pSTAT3 (Y), pSTAT3 (S), and pSTAT1 in the
CD14þþCD16þ intermediate (Figure 3E–G) and the CD14þþCD209þ
monocyte populations (Figure 3H–J). Furthermore, we found that addition
of Stattic to monocyte-HAEC cultures undergoing 10% stretch reduced
upregulation of mRNA for the cytokines IL-6, IL-1b, and IL-23 (Figure 3K).
Next, we sought to determine mechanisms by which endothelial cells
undergoing stretch could activate monocytes and promote STAT3
phosphorylation in adjacent monocytes. Others have reported that
stretch stimulates expression of IL-6 by endothelial cells, and we con-
firmed a two-fold increase in IL-6 protein production by HAECs under-
going cyclical stretch (see Supplementary material online, Figure S4). IL-6
has been shown to both stimulate STAT3 activation and to be produced
in response to STAT3 in a feed-forward fashion.40 Addition of an IL-6
neutralizing antibody to the endothelial/monocyte co-cultures markedly
reduced formation of intermediate monocytes (Figure 4A and B), while
having no effect on the CD14þþCD209þ population (Figure 4C).
STAT3 can also be activated by reactive oxygen species (ROS), includ-
ing hydrogen peroxide.37 ROS, in turn can stimulate IL-6 production by
the endothelium.41 Because increased endothelial stretch can stimulate
ROS formation, we performed additional experiments using Tempol, a
superoxide dismutase mimetic, or polyethylene glycol (PEG)-Catalase,
to scavenge hydrogen peroxide. While Tempol had no effect (data not
shown), we found that PEG-Catalase markedly reduced formation of in-
termediate monocytes in response to 10% endothelial stretch (Figure
4D). Like anti-IL-6, PEG-Catalase did not inhibit formation of the CD209
population (Figure 4E). In keeping with these results with anti-IL-6 and
PEG-Catalase, we found that these interventions also inhibited pSTAT3
(S727) and pSTAT1 (Y701) and exhibited a trend to inhibit pSTAT3
(Y705) (Figure 4F–G) within the intermediate monocytes.
Increased endothelial stretch has also been shown to uncouple the
endothelial NO synthase and to reduce stimulatory phosphorylation of
endothelial NO synthase in endothelial cells.31,42 Likewise NO has been
shown to suppress IL-6-induced STAT3 activation in ovarian cancer
cells.43 We therefore hypothesized that a loss of bioavailable NO might
promote STAT3 activity. In keeping with this hypothesis, we found the
NO donor DETA NONOate (DETA NONO) dramatically reduced
formation of intermediate monocytes (Figure 5A and C) and the activa-
tion of STAT3 (Y), STAT3 (S), and STAT1 when added to monocytes
cultures in the absence of endothelial cells (Figure 5D–F). Furthermore,
addition of this NO donor also reduced formation of CD14þþCD209þ
cells (Figure 5B and G) and activation of STAT3 (Y05), STAT3 (S727), and
STAT1 (Figure 5H–J). We further found that addition of the NO syn-
thase inhibitor L-NAME to monocytes undergoing 5% stretch signifi-
cantly increased pSTAT3 (Y705), pSTAT3 (S272), and pSTAT1 levels in
intermediate monocytes (Figure 5K).
We considered the possibility that LECT2, a ligand for CD209, might
be released by endothelial cells, however we were unable to detect
LECT2 released from HAECs undergoing either 5% or 10% stretch by
ELISA (data not shown). We were also unable to detect release of
HMBG-1 chromatin binding protein, which has been shown to activate
STAT3,44 from stretched endothelial cells (data not shown).
We also examined the hypothesis that monocytes might adhere to
the endothelium and themselves undergo cyclical stretch. In keeping
with this, we found that 10% stretch increased ICAM-1 expression on
endothelial cells and increased adhesion of monocytes to the HAECs
compared to the 5% stretch controls (see Supplementary material on-
line, Figure S5A). We also employed confocal microscopy with Z stacking
to interrogate the endothelial layer and the subendothelial collagen to vi-
sualize CD31þ, CD14þ, and CD83þ cells. Using this approach, we ob-
served CD14þ monocytes on the surface of endothelial cells in the co-
culture (see Supplementary material online, Figure S5B). Moreover,
CD83þ cells were observed on the surface of the CD31þ endothelial
cells exposed to 10% stretch, while none were detected in cultures ex-
posed to 5% stretch. We observed no monocyte or CD83 expressing
cells in the collagen/gelatin sub-endothelial space in either the 5% or 10%
stretch experiments.
To determine if stretch could directly activate monocytes in the ab-
sence of endothelial cells, we cultured monocytes in arginylglycylaspartic
acid (RGD)-covered PronectinVR or Collagen I coated stretch plates
without the presence of HAECs, and exposed these to either 5% or 10%
levels of stretch. By visualizing cells at 24 h, we found that both
PronectinVR and Collagen I coated stretch plates promoted monocyte ad-
hesion (see Supplementary material online, Figure S5C). We examined
monocyte phenotypes following 48 h of stretch on these plates, and
found that neither 5% or 10% stretch in the absence of endothelial cells
supported monocyte transformation (see Supplementary material on-
line, Figure S5D).
3.4 Hypertension affects the distribution of
circulating mononuclear cells in humans
In additional experiments, we sought to determine if hypertension is as-
sociated with an alteration of the phenotype of circulating monocytes.
The demographics of the 132 subjects included for this analysis are
shown in Table 1. Using a gating strategy published previously,35 we
found that there is a progressive decline in the classical monocytes and a
concomitant increase in the percent of intermediate and non-classical
monocytes with increasing levels of hypertension (Figure 6A–C). In addi-
tional studies we sought to determine if intermediate monocytes or
non-classical monocytes exhibit evidence of STAT activation. We
recruited an additional 15 normotensive and 12 hypertensive subjects
for this analysis. The demographics of these subjects are shown in Table
2 and a representative dot plot for the different monocyte populations is
shown in Figure 6D. Example histograms for STAT phosphorylation in
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Figure 3 STAT3 contributes to monocyte differentiation and activation during hypertensive mechanical stretch of endothelial cells. Human CD14þ
monocytes were isolated from PBMCs of normal human volunteers and cultured with HAECs exposed to 10% or 10% stretch plus STAT3 inhibitor (5mM),
Stattic, for 48 h. (A) Flow cytometry gating examples are shown for the CD14þþCD16þ intermediate monocyte population and (B) the CD14þþCD209þ
cells. (C) Individual data point for the effect of Stattic on the number intermediate monocytes and (D) CD14þþCD209þ cells for each subject. (E–G) Effect
of Stattic on total number of cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 within the intermediate monocyte population and (H–J) the
CD14þþCD209þ population. A total of n = 7 participants per group were used. (K) Relative monocyte mRNA expression of IL-6, IL-1b, IL-23 (10%, n= 11;
10%þ Stattic, n = 9), TNFa (n = 7), and CCL4 (n =4) in monocytes. Comparisons were made using one-tail paired t-tests (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001).
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Figure 4 IL-6 and hydrogen peroxide play a role in monocyte transformation and activation. Human CD14þ monocytes were isolated from PBMCs of
normal human volunteers and cultured with HAECs exposed to 10% stretch, 10% plus anti-IL-6 neutralization antibody (10mg/mL) or 10% plus PEG-
Catalase (500 U/mL) for 48 h. (A) Schematic of methods and flow cytometry gating representatives are shown for the CD14þþCD16þ intermediate mono-
cyte population exposed to 10%, 10%þ anti-IL-6, and 10%þ PEG-Catalase. (B) Effect of anti-IL-6 on the total number of intermediate monocytes and (C)
the CD14þþCD209þ cells for each subject. (D) Effect of PEG-Catalase on total number of intermediate monocytes and (E) the CD14þþCD209þ cells for
each participant. (F) Effects of anti-IL-6 and (G) PEG-Catalase on number of cells expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 within the intermediate
monocyte population for each subject. Data with and without these interventions for each subject are shown by the connected lines. A total of n = 6 partici-
pants per group and per experimental treatment were used. Comparisons were made using one-tail paired t-tests (*P < 0.05, **P < 0.01, ***P < 0.001).
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Figure 5 Exposure of monocytes to NO donor inhibits human monocyte conversion and activation to its derived populations. Human CD14þ mono-
cytes were isolated from buffy coats of normal human volunteers and cultured alone in untreated (UT) conditions, DETA-NONOate (DETA-NONO), an
NO donor, at 300mM or DETA-NONO at 1000mM concentrations in static conditions for 48 h. (A) Flow cytometry representatives are shown for the
CD14þþCD16þ intermediate monocyte and (B) the CD14þþCD209þ population. (C) Values for each subject without and with DETA-NONO are shown
for the total number of cells from the CD14þþCD16þ intermediate monocytes and for the total number of cells expressing (D) pSTAT3 (Y), (E) pSTAT3
(S), and (F) pSTAT1 within this population. (G) Effect of DETA-NONO on the number of CD14þþCD209þ cells and the expression of (H) pSTAT3 (Y), (I)
pSTAT3 (S), and (J) pSTAT1 for each subject. A total of n= 9 participants per group were used for these experiments. (K) Human CD14þmonocytes were
cultured with HAECs exposed to 5% stretch or 5% plus NO synthase inhibitor, L-NAME (1000mM) for 48 h. The number of CD14þþCD16þ intermediate
monocyte population expressing pSTAT3 (Y), pSTAT3 (S), and pSTAT1 for each subject are connected by lines. A total of n = 7 participants per group
were used. For (C–J) the nonparametric Friedman’s test followed by Dunn’s multiple comparison tests was employed. For (K) a one-tailed paired t-tests was
used (*P < 0.05, **P < 0.01, ***P < 0.001).
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.normotensive and hypertensive individuals are shown in Figure 6E.
Intermediate monocytes exhibited increased phosphorylation of STAT3
Y705, STAT3 S727, and STAT1 Y701 compared with other monocyte
populations (Figure 6F–H). No differences between normotensive and
hypertensive groups were observed.
3.5 Angiotensin II-induced hypertension in
WT C57Bl/6 mice promotes accumulation
of myeloid cells containing activated
STAT3 in the kidney and aorta
In subsequent experiments, we sought to determine the role of hyper-
tension on monocyte transformation in vivo. We induced hypertension in
C57Bl/6 mice by infusion of Ang II (490 ng/kg/min) for 6 days and
analysed single cell suspensions of the kidney, aorta, spleen, and peri-
aortic lymph nodes for the presence of monocytes, macrophages (MU)
and DCs using a gating strategy that effectively allows discrimination of
these cells (Figure 7A). We found a significant increase in the total num-
ber of macrophages (Figure 7B) and DCs (Figure 7C) and a trend of an in-
crease in the monocytes (Figure 7D) within the aorta of Ang II treated
mice. This increase in cell number was accompanied by an increase in
STAT3 (Y705) activation (Figure 7E and F) and a trend of an increase in
the monocyte population (Figure 7G). We also found an increase in mac-
rophages, DCs and monocytes in the Ang II treated mice within the kid-
neys (Figure 7H–J) and an increase in STAT3 activation in each of these
populations (Figure 7K–M). In the lymph nodes, macrophages were in-
creased in response to Ang II infusion, while there was no change in
monocytes or DCs (see Supplementary material online, Figure S6A). We
also observed an increase in STAT3 activation of monocytes in lymph
nodes. There were no major changes in these populations and in STAT3
activation in the spleen of Ang II-treated mice (see Supplementary mate-
rial online, Figure S6B). To determine the location of monocytes infiltrat-
ing the aorta after 2 weeks of Ang II infusion in C57Bl/6 mice, we
performed immunofluorescence of aortic sections for F4/80 (red),
pSTAT3 (Y705, green), and DAPI. We found that after 2 weeks of Ang II
infusion, monocytes and macrophages localize in the perivascular fat and
adventitia and these co-localize with pSTAT3 (Y705) (see
Supplementary material online, Figure S7) (Figure 8).
4. Discussion
In this study, we demonstrate that exposure of human monocytes to en-
dothelial cells undergoing 10% mechanical stretch increases differentia-
tion into CD14þþCD16þ intermediate monocytes and
CD14þþCD209þ cells. We further show that monocytes cultured with
endothelial cells exposed to hypertensive mechanical stretch markedly
increase expression of IL-6, IL-1b, IL-23, CCL4, and TNFa and have en-
hanced ability to drive proliferation of T cells from the same human do-
nor. In addition, we found that endothelial cells undergoing hypertensive
mechanical stretch stimulate an increase in pSTAT3 (Y), pSTAT3 (S),
and pSTAT1 within these monocyte populations. Inhibition of STAT3 by
Stattic prevented conversion of monocytes into the intermediate and
the DC phenotype and normalized the cytokine production of these
monocytes cultured with endothelial cells undergoing 10% stretch. Our
data implicate a role of hydrogen peroxide and IL-6 as mediators of
monocyte differentiation. We also show that hypertension is associated
with an increase in the percentage of circulating intermediate and non-
classical monocytes and that circulating intermediate monocytes exhibit
higher levels of pSTAT3 (Y), pSTAT3 (S), and pSTAT1. Finally, the tissue
infiltrating monocytes, macrophages, and DCs exhibited an increase in
phosphorylated STAT3 in hypertensive mice. Thus, altered mechanical
forces affecting the endothelium can modify monocyte differentiation
and activation and likely contribute to immune activation in
hypertension.
..............................................................................................................................................................................................................................
Table 1 Clinical characteristics of patients studied for comparison of circulating monocytes (n¼132)
NT HTN well
controlled
HTN poorly
controlled
P value
(ANOVA or v2)
Age 58.1 ± 12 59.8 ± 10.9 62 ± 10 NS
Race (W/B) 20/0 52/0 60/0 –
Sex (M/F) 13 Jul 24/28 27/33 NS
BMI 26.1 ± 2.7 28.8 ± 5.7 28.0 ± 4.7 NS
SBP 120 ± 10 127 ± 8 147 ± 13 <0.001
DBP 77 ± 10 81 ± 7 90 ± 8 <0.001
Cholesterol 5.6 ± 1.4 5.2 ± 1.5 5.5 ± 1.3 NS
Smoking 20 May 16/52 16/60 NS
Hypercholesterolemia 20 Nov 35/52 48/60 NS
Medications (n) Pearson v2
ACEi 3 41 55 <0.002
CCB 1 14 36 <0.01
BB 5 33 39 0.4
Diuretic 1 25 50 <0.001
ARB 0 5 5 0.7
a1B 0 2 12 <0.02
Statin 8 26 31 0.8
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin AT1-receptor blocker; BB, beta-blocker; a1B, alpha-1 adrenergic receptor antagonist; CCBþBB, nifedipine and
metoprolol; CCBþ a1B, amlodipine and doxazosin.
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..Intermediate monocytes are the least characterized of the monocyte
subtypes in humans, however, these cells have been implicated in inflam-
matory diseases such as Kawasaki disease,45 rheumatoid arthritis,15
sepsis,46 HIV,47 acute heart failure, and coronary artery disease.48 Using
deuterium labelling in humans, Patel et al. recently showed a sequential
transition of classical monocytes that emerge from the bone marrow to
the intermediate and subsequently the non-classical phenotype.11
Compared with classical monocytes, intermediate monocytes exhibit
Figure 6 Hypertension affects the distribution of circulating monocytes in humans. (A) A cohort of normotensive (n = 20), mildly hypertensive (systolic
BP130–140 mmHg, n = 52), and severely hypertensive (systolic BP >140 mmHg, n = 60) subjects were recruited and flow cytometry was used to analyse
various monocyte populations. (A) Mean values are shown for the percent of positive CD14þþCD16- classical, (B) CD14þþCD16þ intermediate and (C)
CD14lowCD16þþ non-classical monocytes comparing normotensive, mild, and severely hypertensive subjects. Data were analysed using one-way ANOVA.
(D) Representative flow cytometry dot plots showing classical, intermediate, and non-classical subset distribution are shown. (E) Histograms showing the
CD14þþCD16- classical, CD14þþCD16þ intermediate, non-classical monocyte population comparing normotensive (black) and hypertensive (red) sub-
jects. The dashed line represents the Mean fluorescent intensity (MFI) for the FMO control. (E) MFI for pSTAT3 (Y), pSTAT3 (S) (F), and pSTAT1 (G) in vari-
ous monocyte subgroups in both normotensive (n = 15) and hypertensive (n = 12) subjects. Two-way ANOVA with Student Newman Keuls post hoc test
was used (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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enhanced phagocytosis, produce higher levels of ROS and inflammatory
mediators such as TNFa and IL-1b.12,49,50 They also have the highest ex-
pression of the major histocompatibility complex class II antigens, includ-
ing histocompatibility leukocyte antigen (HLA)-DR, -DP, and -DQ
indicating that they also possess antigen presentation functions.51 Thus,
the presence of high numbers of intermediate monocytes in humans
with hypertension likely has pathophysiological implications.
Our data are compatible with findings by Randolph et al. showing that
activated endothelial cells can modify monocyte phenotype. They dem-
onstrated that monocytes that transmigrate the endothelium convert to
macrophages that remain in the subendothelial space or DCs expressing
CD83 that reverse transmigrate the endothelium.22 In a subsequent
study, this group also showed that a subpopulation of CD16þ mono-
cytes have a propensity to reverse transmigrate the endothelium and,
upon doing so, increase their expression of CD86þ and HLA-DR. In
keeping with this, the authors showed these monocytes potently in-
duced allogenic T-cell proliferation.23 The investigators assumed cells
had transmigrated the endothelial monolayer if they were not removed
by washing the monolayer 2 h after addition of the cells. In our study, we
found that 10% stretch markedly enhanced monocyte binding to the en-
dothelial surface. Our analysis, however, did include cells potentially
within the subendothelial space and it also demonstrated the presence
of macrophage-like cells expressing the CD163 marker; however, these
were not altered by the degree of endothelial stretch.
In these experiments, we not only examined intermediate and non-
classical monocytes, but also CD14þ cells bearing the markers CD209
and CD83. These have been employed as DC markers, but can be
expressed on a variety of activated myeloid cells. CD209 is a C-type
Lectin receptor that promotes the production of IL-1b and IL-23 that
can ultimately skew T cells to a TH17 phenotype. Levels of CD209 on
whole leukocytes correlate with disease severity in Behçet’s Disease.52
LECT2 acts on CD209 to induce c-Jun N-terminal kinase (JNK) signalling
in monocytes and endothelial cells.20 CD209 forms a complex with
TLR4 and promotes NFjB activation in response to oxidized low-
density lipoprotein (LDL) confirming the role of CD209 in innate immu-
nity and antigen presentation.53 While we were not able to detect
LECT2 levels in our co-culture system, the increase in CD209 on mono-
cytes could arm these cells to respond to signals such as LECT2 or oxi-
dized LDL in vivo. CD83 is a type-I lectin transmembrane protein
expressed on monocyte-derived DCs and small subsets of other im-
mune cells.54 The presence of CD83 on DCs enhances their ability to
evoke T-cell calcium transients and proliferation.36 Thus, surface expres-
sion of CD209 and CD83 may have functional consequences in enhanc-
ing immunogenicity of monocyte-derived cells in hypertension.
There are a number of factors in the hypertensive milieu that could
activate both endothelial cells and monocytes, including cytokines and
oxidative stress.55,56 In this investigation, we focused on the role of in-
creased endothelial stretch, which is known to stimulate endothelial cell
cytokine production, ROS formation and expression of adhesion mole-
cules.31 The vessels affected by stretch in hypertension likely vary
depending on the duration of the disease. Early in hypertension, there is
increased stretch of large arteries; however, as hypertension is sustained,
these proximal vessels become stiff, leading to propagation of the for-
ward pulse wave velocity into smaller resistance arteries.57 Our present
data therefore might explain how increased cyclic stretch in small vessels
could promote immune activation. Consistent with this, we have previ-
ously shown that aortic stiffening precedes renal accumulation of T cells,
monocyte and macrophages ultimately leading to renal dysfunction.58
In these experiments, we found evidence for STAT activation in inter-
mediate monocytes of humans and in monocytes exposed to endothelial
cells undergoing 10% cyclical stretch as evidenced by phosphorylation of
STAT1 at Y701 and STAT3 at S727 and Y705. Of interest, STAT3 is re-
quired for Flt3-dependent formation of DCs from bone marrow derived
cells,38 and plays an important role in production of IL-1b, IL-6, and
TNFa in macrophages of humans with coronary artery disease.37 We
also found that exposure of monocytes to endothelial cells undergoing
10% stretch markedly enhanced mRNA expression of these cytokines
and that STAT3 is activated in these cells. Inhibition of STAT3 with
Stattic not only inhibited cytokine production by human monocytes, but
also reduced their conversion to intermediate monocytes and
CD14þþCD209þ cells. Thus, STAT-signalling seems to play an impor-
tant role in monocyte differentiation and activation in hypertension. In
keeping with this, we also observed an increase in STAT3 activation the
monocyte-derived cells in the aorta and kidney of mice with Ang II-
induced hypertension. These results are compatible with findings of
Johnson et al., who showed that STAT3 inhibition with S3I-201 pre-
vented Ang II-induced hypertension and vascular dysfunction in vivo.59
We made substantial efforts to identify factors released by the endo-
thelium that would mediate STAT3 activation. STAT3 can be activated by
myriad factors, including growth factors, numerous cytokines, Janus tyro-
sine kinase (JAK), ROS, heat shock proteins and xenobiotics.60 IL-6 is
both upstream and downstream of STAT3 activation, and we found that
endothelial cells undergoing 10% stretch produced increased amounts of
this cytokine. This is compatible with prior gene profiling studies showing
that cyclical stretch increases IL-6 expression in endothelial cells.28 We
found that immune-clearing of IL-6 inhibited STAT3 activation and mono-
cyte transformation to the intermediate phenotype suggesting a scenario
in which IL-6 released by the endothelium stimulates STAT3 activation in
adjacent monocytes, and ultimately greater amounts of IL-6 production
by these latter cells in a feed-forward fashion. Of note, IL-6 quartiles were
found to be strongly associated with the risk of developing hypertension
......................................................................................................
Table 2 Demographics of patients studied for analysis of
phospho-STAT in circulating monocytes
Normotensive P Hypertensive
n 15 12
Age (years) 44.8±3.9 NS 51.3±2.6
Race (W/B) 15/0 NS 3 Sep
Gender (F/M) 4-Nov NS 3 Sep
BMI (Kg/m2) 26.6±1.3 <0.03 34.7±2.9
SBP (mmHg) 110.8±3.7 <0.00003 140.5±4.1
DBP (mmHg) 64.4±1.6 <0.003 78.7±3.6
Drug Rx
None 15 2
ACEi 0 4
ARB 0 1
HCTZþACEi 0 2
HCTZþARB 0 1
CCBþBB 0 1
CCBþa1B 0 1
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin AT1-receptor
blocker; HCTZ, hydrochlorothiazide; BB, beta-blocker; a1B, peripheral alpha-1
adrenergic receptor antagonist; CCBþ BB, nifedipine and metoprolol;
CCBþ a1B, amlodipine and doxazosin.
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Figure 7 Angiotensin II-induced hypertension in wildtype C57Bl/6 mice promotes an increase in STAT3 phosphorylation in the immune cells from kidney
and aorta. (A) Representative flow cytometry dot plots showing the gating strategy to identify macrophages, DCs and monocytes from C57Bl/6 wildtype
mice infused with Ang II (490 ng/kg/min) or sham for 6 days. (B–D) Mean values of absolute numbers of indicated cell types per thoracic aorta. (E) Mean val-
ues of pSTAT3 (Y) expression within the macrophage (M/), (F) DC and (G) monocyte populations per thoracic aorta. (H–J) Mean values of absolute num-
bers of indicated cell types per kidney. (K) Mean values of pSTAT3 (Y) expression within the macrophage, (L) DC and (G) monocyte populations per kidney.
A total of n = 5, sham, and n =7, Ang II, treated mice per group were used. One-tail unpaired t-test was employed (*P < 0.05, **P < 0.01, ***P < 0.001).
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..in the Nurses Health Study,61 and mice lacking this cytokine are protected
against Ang II-induced hypertension.62
We also found that PEG-Catalase, which scavenges hydrogen perox-
ide, prevents monocyte transformation and STAT3 activation. This find-
ing is compatible with prior studies showing that cyclical stretch activates
production of ROS by endothelial cells, initially via activation of the
NADPH oxidase and subsequently from uncoupled NO synthase.31 In
preliminary studies, we confirmed that superoxide production, as mea-
sured by detection of 2-hydroxyethidium formation from dihydroethi-
dium, was increased in both monocytes and endothelial cells when the
latter cells were exposed to 10% vs. 5% stretch (data not shown). Our
data suggest that superoxide is unlikely the mediator of monocyte trans-
formation, as the superoxide dismutase mimetic Tempol failed to pre-
vent formation of intermediate cells or STAT3 activation. It is therefore
likely that hydrogen peroxide, formed by dismutation of superoxide,
mediates these effects. Hydrogen peroxide is relatively stable and thus
likely to serve a paracrine-signalling role in mediating cross talk between
the endothelium and adjacent monocytes. Of interest, the expression of
haeme oxygenase, which has anti-oxidant properties, inversely corre-
lates with monocyte expression of CD14 in humans.63
In our experimental setup, we cannot exclude the possibility that IL-6
and hydrogen peroxide also have effects on the endothelium. Activation of
the IL-6 receptor has been shown to stimulate the JAK-STAT pathway that
can lead to further IL-6 production.64 Likewise, hydrogen peroxide can acti-
vate the NADPH oxidase, which could ultimately lead to additional hydro-
gen peroxide production in a feed forward fashion.65 We have also shown
that ROS released from the mitochondria can stimulate the NADPH oxi-
dase in endothelial cells.66 Thus, the production of IL-6 and hydrogen per-
oxide in a milieu of endothelial cells and monocytes could have actions on
both cell types, but ultimately lead to monocyte differentiation.
Another potential mediator of STAT activation is loss of NO signal-
ling. NO has been shown to inhibit STAT3 activation in ovarian cancer
cells and endothelial NO bioavailability is commonly lost in hypertension
and related diseases.67,68 Monocytes in the circulation are constantly ex-
posed to endothelial-derived NO, however, when placed in culture,
spontaneously acquire CD16. We confirmed this in our studies and
found that this was associated with STAT3 phosphorylation and that the
NO donor DETA-NONOate markedly inhibited monocyte transforma-
tion and STAT activation. We also found that the addition of L-NAME to
monocyte-HAECs cultures undergoing 5% stretch promoted STAT acti-
vation, in a fashion similar to 10% stretch. L-NAME exposure did not
cause monocyte transformation during this 48-h exposure, suggesting
that other signals like IL-6 and hydrogen peroxide might also be needed
for this response. In keeping with our findings in the co-culture experi-
ments, we found that hypertensive humans have an increase in circulat-
ing intermediate and non-classical monocytes, and that that this seems
dependent on their severity of hypertension. It is likely that this shift in
monocyte population predisposes to further inflammatory responses, in-
cluding production of cytokines and T-cell activation. Of note, we also
confirmed that intermediate monocytes of both hypertensive and nor-
motensive subjects exhibit STAT1 and STAT3 activation. This is compat-
ible with a scenario in which intermediate monocytes consistently
exhibit and likely require STAT activation for their transformation from
the classical precursors, but that this transformation is higher in hyper-
tension, perhaps due to encounter with activated endothelium.
In summary, our current study provides a previously unrecognized
link between mechanical forces affecting the endothelium and activation
of monocytes. This provides new insight into how the immune system
can be activated in hypertension and for the first time implicates interme-
diate monocytes as potentially important in this disease. Intermediate
Figure 8 Increased endothelial stretch promotes monocyte transformation and activation. Under physiological stretch, the endothelium releases nitric
oxide that prevents monocyte activation and transformation. In hypertension, increased vascular stretch promotes endothelial activation. The activated en-
dothelium in turn releases ROS including hydrogen peroxide, cytokines including IL-6 and exhibits reduced NO bioavailability. These events initiate STAT3
activation in the monocytes and promote transformation of the classical monocyte into an intermediate and subsequently a non-classical monocyte as well
as a cells bearing the CD209 DC marker.
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.
monocytes are not only a biomarker of inflammation in hypertension,
but their acquisition of CD16 arms them to possess cytotoxic function
and to produce TNFa. The production of cytokines like IL-6, IL-23, and
IL-1b can also skew T cells produce IL-17A, which we have previously
shown to be involved in hypertension.8 It is therefore likely that altered
endothelial mechanical forces have important effects on immune cell
function, leading to end organ dysfunction and worsening hypertension.
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